First Commonwealth Financial Corp
Change company Symbol lookup
Select an option...
FCF First Commonwealth Financial Corp
PTOTF Patriot One Technologies Inc
GIM Templeton Global Income Fund
NSTC Northern Star Investment Corp III
WMLLF Wealth Minerals Ltd
NVVE Nuvve Holding Corp
ICCC ImmuCell Corp
MET MetLife Inc
FAST Fastenal Co
PFTA Portage Fintech Acquisition Corp
Go

Financials : Banks | Small Cap Value
Company profile

First Commonwealth Financial Corporation is a financial holding company for First Commonwealth Bank (the Bank). First Commonwealth Bank is a Pennsylvania bank and trust company. The Bank provides a diversified array of consumer and commercial banking services. It also provides trust and wealth management services and offers insurance products through the Bank and its other operating subsidiaries. The Bank operates approximately 118 community banking offices throughout western and central Pennsylvania, and northeastern, central and southwestern Ohio, as well as corporate banking centers in Pittsburgh, Pennsylvania, and Columbus, Canton and Cleveland, Ohio, and mortgage banking offices in Wexford, Pennsylvania, and Hudson, Westlake and Lewis Center, Ohio. The Bank also operates a network of approximately 136 automated teller machines (ATMs), at various branch offices and offsite locations.

Price
Delayed
$14.49
Day's Change
0.015 (0.10%)
Bid
--
Ask
--
B/A Size
--
Day's High
14.53
Day's Low
14.39
Volume
(Light)

Today's volume of 51,337 shares is on pace to be much lighter than FCF's 10-day average volume of 338,523 shares.

51,337

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Kiromic To Contact Him Directly To Discuss Their Options

5:45 pm ET October 4, 2022 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / October 4, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ:KRBP) and reminds investors of the October 4, 2022 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you suffered losses exceeding $100,000 investing in Kiromic: (1) common stock pursuant and/or traceable to the Offering Documents and/or (2) securities between June 25, 2021 and February 2, 2022, both dates inclusive (the "Class Period"). Plaintiff pursues claims against Defendants under the Securities Act of 1933 and the Securities Exchange Act of 1934. and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/KRBP.

Faruqi & Faruqi, LLP, Wednesday, September 21, 2022, Press release picture

There is no cost or obligation to you.

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.

The Complaint alleges that the Offering Documents failed to disclose that the FDA had, prior to the filing of the Registration Statement and Prospectus, imposed a clinical hold, and in fact, contained statements indicating that it had not. Given that the Offering closed on July 2, 2021, more than thirty (30) days after the Company submitted the IND applications for its two immunotherapy product candidates, investors were assured that no clinical hold had been issued and clinical trials would commence.

The Company, however, had received communications from the FDA on June 16 and 17, 2021, informing it that the FDA was placing the IND applications for its two candidate products on clinical hold. The Offering Documents failed to disclose this information, instead representing that clinical testing was expected to proceed in the third quarter of 2021. Clinical testing did not proceed in the third quarter of 2021, nor was it likely given the FDA's imposition of a clinical hold.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Kiromic's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE: Faruqi & Faruqi, LLP





View source version on accesswire.com:

https://www.accesswire.com/718877/Securities-Litigation-Partner-James-Josh-Wilson-Encourages-Investors-Who-Suffered-Losses-Exceeding-100000-In-Kiromic-To-Contact-Him-Directly-To-Discuss-Their-Options



comtex tracking

COMTEX_415922155/2457/2022-10-04T17:45:15

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.